Overview

Postmenopausal Estrogen/Progestin Interventions (PEPI)

Status:
Completed
Trial end date:
2000-10-01
Target enrollment:
0
Participant gender:
Female
Summary
To assess the effects of various postmenopausal estrogen replacement therapies on selected cardiovascular risk factors, including high density lipoprotein cholesterol, systolic blood pressure, fibrinogen, and insulin and on osteoporosis risk factors. Conducted in collaboration with the National Institute of Child Health and Human Development, the National Institute of Arthritis and Musculoskeletal and Skin Diseases, The National Institute of Diabetes and Digestive and Kidney Diseases, and the National Institute on Aging. The extended follow-up is for 3 years focusing on endometrium and breast evaluation.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
National Heart, Lung, and Blood Institute (NHLBI)
Collaborators:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institute on Aging (NIA)
Treatments:
Estrogens
Estrogens, Conjugated (USP)
Medroxyprogesterone
Medroxyprogesterone Acetate
Progesterone
Criteria
Postmenopausal women, ages 45 to 64. One third of the subjects had had a hysterectomy.